Consolidated Company Outline

Company Name Olympus Corporation
Market Tokyo Stock Exchange, Prime Market
Stock Code ISIN: JP3201200007
Established October 12, 1919
Head Office 2951 Ishikawa-machi, Hachioji-shi, Tokyo 192-8507, Japan

Map

Share Capital 124.643 billion yen (As of March 31, 2024)
Consolidated Revenue 936.2 billion yen (Fiscal year ended March 31, 2024)
Consolidated Headcount 28,838 (As of March 31, 2024)

Revenue by Business Divisions

Fiscal year ended March 2024: Consolidated revenue 936.2 billion Yen. Share of revenue by business segment: Endoscopic Solutions 586.6 billion Yen 62.7%, Therapeutic Solutions 337.3 billion Yen 36.0%, and Other 12.3 billion Yen 1.3%.

Number of Group Companies

92 (Excluding Olympus Corporation)

Revenue and Operating Profit

Revenue and operating profit, fiscal year ended March: 2020 Revenue 755.2 billion Yen, operating profit 92.2 billion Yen. 2021 Revenue 730.5 billion Yen, operating profit 82.0 billion Yen. 2022 Revenue 868.9 billion Yen, operating profit 153.9 billion Yen. 2023 Revenue 881.9 billion Yen, operating profit 186.6 billion Yen. 2024 Revenue 936.2 billion Yen, operating profit 43.6 billion Yen.

Note) We split off the imaging business to a special purpose company established by Japan Industrial Partners, Inc. on January 1, 2021. In this regard, imaging division is categorized as a discontinued operation, effective Q2 of FY2021 and figures of FY2020 is restated.

Revenue by Region

Fiscal year ended March 2024: Consolidated revenue 936.2 billion Yen. Japan 121.5 billion Yen 13%, North America 351.3 billion Yen 38%, Europe 242.8 billion Yen 26%, China 106.3 billion Yen 11%, Asia and Oceania 88.1 billion Yen 9%, Other Region 26.1 billion Yen 3%.Fiscal year ended March 2024: Consolidated revenue 936.2 billion Yen. Japan 121.5 billion Yen 13%, North America 351.3 billion Yen 38%, Europe 242.8 billion Yen 26%, China 106.3 billion Yen 11%, Asia and Oceania 88.1 billion Yen 9%, Other Region 26.1 billion Yen 3%.